Aquestive Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Chief Executive Officer Daniel Barber adopted a written sales plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act (the "Barber Plan") on September 15, 2025. The Barber Plan will commence on December 15, 2025 and ends on January 29, 2027. The maximum number of shares to be sold under the Barber Plan is 485,500 shares and no shares have been sold as of the date of this Report; the actual number of shares sold will be dependent on the satisfaction of certain conditions set forth in the Barber Plan.
Director Julie Krop adopted a written sales plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act (the "Krop Plan") on September 15, 2025. The Krop Plan will commence on December 15, 2025 and ends on June 30, 2026. The maximum number of shares to be sold under the Krop Plan is 88,000 shares and no shares have been sold as of the date of this Report; the actual number of shares sold will be dependent on the satisfaction of certain conditions set forth in the Krop Plan.
Chief Operating Officer Cassie Jung terminated her 10b5-1 plan on October 21, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.